Company Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
0.291 ^USD	+1.89%		-13.00%	-79.06%

19/03	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT
19/03	Seelos Therapeutics' ALS treatment fails in mid-stage study	RE

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Number of employees: 16

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	0	nan %	2	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	nan %	2	100.0 %	-

Managers	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	64	01/87/01
Michael Golembiewski DFI	Director of Finance/CFO	52	01/19/01
Karen Fusaro CTO	Chief Tech/Sci/R&D Officer	-	-
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-
Timothy J Whitaker CTO	Chief Tech/Sci/R&D Officer	66	-
Anthony Marciano IRC	Investor Relations Contact	-	01/17/01
Lucas Pilipski PRN	Corporate Officer/Principal	-	01/20/01

Members of the board	Title	Age	Since
Margaret Dalesandro BRD	Director/Board Member	77	01/21/01
Richard Pascoe BRD	Director/Board Member	60	01/13/01
Daniel O'Connor BRD	Director/Board Member	59	01/19/01
Brian Lian BRD	Director/Board Member	58	01/19/01
Raj Mehra CEO	Chief Executive Officer	64	01/87/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	13,680,576	13,406,690 ( 98.00 %)	0	98.00 %

Name	Equities	%	Valuation
The Lind Partners LLC 6.698 %	916,365	6.698 %	541 572 $
Wealth Effects LLC 3.411 %	466,660	3.411 %	275 796 $
Horizons ETFs Management (Canada), Inc. 2.220 %	303,714	2.220 %	179 495 $
Vanguard Global Advisers LLC 2.075 %	283,878	2.075 %	167 772 $
Balyasny Asset Management LP 1.935 %	264,754	1.935 %	156 470 $
Raj Mehra 1.353 %	185,143	1.353 %	109 420 $
AdvisorShares Investments LLC 1.325 %	181,259	1.325 %	107 124 $
Tontine Associates LLC 0.8159 %	111,615	0.8159 %	65 964 $
Michael Golembiewski 0.6350 %	86,869	0.6350 %	51 340 $
Morgan Stanley & Co. LLC 0.5129 %	70,163	0.5129 %	41 466 $

Name	Equities	%	Valuation
REGNUM CORP. 98.82%	22,680,000	98.82%	725,760 $

Seelos Therapeutics, Inc.

300 Park Avenue 2nd Floor

10022, New York

http://www.seelostherapeutics.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SEELOS THERAPEUTICS, INC.	-79.06%	3.98M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs